bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: Association with clinical outcome

Clinical Cancer Research

Volumn 2, Issue 12, 1996, Pages 2015-2022

  Sinicrope, Frank A ^a   Evans, Douglas B ^a   Leach, Steven D ^a   Cleary, Karen R ^a   Fenoglio, Claudia J ^a   Lee, J Jack ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; PROTEIN BCL 2; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030443653     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Wingo, A. P., Tong, T , Bolden, S., Squires, T. S., and Taong, T. Cancer statistics, 1995. CA Cancer J. Clin., 5: 3-30, 1995.
2. Hruban, R. H., van Mansfeld, A D. M., Offerhaus, G. J., van Weering, D. H J., Allison, D. C., Goodman, S. N., Kensler, T. W., Bose, K. K , Cameron, J. L., and Bos, J. L. K-ras oncogene activation in adenocarcinoma of the human pancreas A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol., 143: 545-554, 1993.
3. Almoguerra, C., Shibata, D., Forrester, K , Martin, J., Arnheim, N., and Perucho, M Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53: 549-554, 1988.
4. Pellegata, N. S., Sessa, F., Renault, B., Bonato, M., Leone, B. E., Solcia, E., and Ranzani, G. N. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res., 54: 1556-1560, 1994.
5. Redston, M. S., Caldas, C., Seymour, A. B., Hruban, R. H., daCosta, L. T., Yeo, C. J., and Kern, S. E. p53 mutations in pancreatic carcinomas and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res , 54: 3025-3033, 1994.
6. Lee, E. Y., Cibull, M. L., O'Daniel-Pierce, E., Strodel, W. E., and Jennings, C. D. Expression of p53 protein in pancreatic adenocarcinoma. Int. J. Pancreatol., 17: 237-242, 1995.
7. Zhang, S. Y., Ruggeri, B., Agarwal, P., Sorling, A. F., Obara, T., Ura, H., Namiki, M., and Klein-Szanto, A. J. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch. Path. Lab. Med., 118: 150-154, 1994.
8. Barton, C. M., Staddon, S. L., Hughes, C. M., Hall, P. A., O'Sullivan, C , Kloppel, G., Theis, B., Rusell, R. C., Neoptolemos, J., and Williamson, R. C. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br. J. Cancer, 64: 1076-1082, 1991.
9. DiGiuseppe, J. A., Hruban, R. H., Goodman, S. N., Allism, D. A., Cameron, J. L., and Offerhaus, J. G. A. Overexpression of p53 tumor suppressor protein in pancreatic adenocarcinoma. Am. J. Clin. Pathol., 101: 684-688, 1994.
10. Caldas, C., Hanh, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C., and Kent, S. E. Frequent somatic mutations and homozygous deletions of the p16 (MST1) gene in pancreatic adenocarcinomas. Nat. Genet., 8: 27-32, 1994.
11. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell. 78: 539-542, 1994.
12. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
13. Miyashita, T., and Reed, J bcl-2 gene transfer increases relative resistance of S49 1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res., 52: 75407-5411, 1992.
14. Hockenberry, D., Zutter, M., Hickey, W., Nahm, M., and Korsmeyer, S. J. Bcl-2 protein is topographically restricted to tissue characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA, 85: 6961-6965, 1991.
15. Sinicrope, F. A., Ruan, S., Cleary, K. R., Lee, J. J., and Levin, B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res., 55: 237-241, 1995
16. Hague, A., Moorghen, M., Hicks, D., Chapman, M., and Paraskeva, C. bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene. 9: 3367-3370, 1994.
17. Sinicrope, F. A., Hart, J., Michelassi, F. M., and Lee, J. J. Prognostic value of bcl-2 oncoprotein expression in Stage II colon carcinoma. Clin. Cancer Res., 1: 1103-1110, 1995.
18. Öfner, D., Riehemann, K., Maier, H., Reidmann, B , Nehoda, H., Totsch, M., Bocker, W., Jasani, B., and Schmid, K. W. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br. J. Cancer, 72: 981-985, 1995.
19. Baretton, G. B., Diebold, J., Christoforis, G., Vogt, M., Müller, C., Dopfer, K., Schneiderbanger, K., Schmidt, M., and Lohrs, U. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas: aspects of carcinogenesis and prognostic significance. Cancer (Phila.), 77: 255-264, 1996.
20. Silvestrini, R., Veneroni, S , Daidone, M. G., Benini, E., Boracchi, P, Mezzetti, M., Di Fronzo, G., Rilke, F., and Veronesi, U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 86: 499-504, 1994.
21. Joensuu, H., Pylkkanen, L., and Toikkanen, S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol., 145: 1191-1198, 1994.
22. Gasparini, G., Barbareschi, M , Doglioni, C., Dalla Palma, P., Angelo Mauri, F. A., Borrachi, P., Bevilacqua, P., Caffo, O., Morelli, L., Verderio, P., Pezzella, F , and Harris, A. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res., 1. 189-198, 1995.
23. Herod, J. J. O., Eliopoulos, A. G., Warwick, J., Niedobitek, G., Young, L. S., and Kerr, D. J. The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res., 56: 2178-2184, 1996.
24. Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B , Harris, B., Gatter, K. C., and Mason, D. Y. bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med., 329: 690-694, 1993.
25. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
26. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
27. Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711, 1994.
28. Greenblatt, M. S., Bennett, W P , Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
29. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E , Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
30. Yeo, C. J., Cameron, J. L., Lillemore, K. D., Sitzmann, J. V., Hruban, R. H., Goodman, S. N., Dooley, W. C., Coleman, J., and Pitt, H. A. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann. Surg., 227: 721-731, 1995.
31. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer (Phila.), 59: 2006-2010, 1987.
32. Foo, M. L., Gunderson, L. L., Nagorney, D. M., McLlrath, D. C., van Heerden, J. A., Robinow, J. S., Kvols, L. K., Garton, G. R., Martenson, J. A., and Cha, S. S. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation = 5-fluorouracil. Int. J. Radiat. Oncol. Biol. Phys., 26: 483-489, 1993.
33. Evans, D. B., Abbruzzese, J. L., Lee, J. E., Leach, S. D., Chamsangavej, C , Cleary, K. R., Buchholz, D., and Rich, T. A. Preoperative chemoradiation for adenocarcinoma of the pancreas. MD Anderson experience. Semin. Surg. Oncol., 11. 132-140, 1995.
34. Evans, D B., Rich, T. A., Byrd, D. R., Cleary, K. R., Connelly, J. H., Levin, B , Charnsangavej, C., Fenoglio, C. J., and Ames, F. C. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch. Surg., 127: 1335-1339, 1992.
35. Staley, C. A., Cleary, K. R., Abbruzzese, J. L., Lee, J. E., Ames, F. C., Fenoglio, C. J., and Evans, D B. The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas, 12: 373-379, 1996.
36. Cox, P. R., and Oakes, D. Analysis of Survival Data. New York: Chapman and Hall, 1984.
37. Sperti, C , Bonadomani, B., Pasquali, C, Piccoli, A., Cappellazzo, F., Rugge, M., and Pedrazzoli, S. Ductal adenocarcinoma of the pancreas. Clinicopathologic features and survival. Tumori, 79: 325-330, 1993.
38. Laurent-Puig, P., Olschwang, S., Delattre, O. Remvikos, Y., Asslain, B., Melot, T., Validire, P., Muleris, M., Girodet, J , Salmon, R. J., and Thomas, G. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology, 102: 1136-1141, 1992.
39. Maestro, R., Dolcetti, R., Gasparotto, D., Doglioni, C., Pelucchis, S., Barzan, L., Grandi, E., and Boiocchi, M. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene, 7: 1159-1166, 1992.
40. Momand, J., Zambetti, G. P., Olsen, D. C., George, D., and Levine, A. J. The indin-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
41. Chiou, S-K., Rao, L., and White, E Bcl-2 blocks p53-dependent apoptosis. Mol. Cell Biol., 14: 2556-2563, 1994.
42. Han, J., Sabbatini, P., Perez, D., Rao, L., Modha, D., and White, E. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death promoting Bax protein. Genes Dev., 10: 461-477, 1996.
43. Pietenpol, J. A., Papadopoulos, N., Markowitz, S., Willson, J. K. V., Kinzler, K. W., and Vogelstein, B. Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res., 54: 3714-3717, 1994.
44. Borner, C. Diminished cell proliferation associated with death-protective activity of bcl-2. J Biol. Chem., 22: 12695-12698, 1996.
45. Uhlmann, E. J , D'Sa-Eipper, C., Subramanian, T., Wagner, A. J., Hay, N., and Chinnadurai, G. Deletion of nonconserved region of bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation. Cancer Res., 56. 2506-2509, 1996.
46. Korsmeyer, S. J Molecular thanatopsis: a discourse on the bcl-2 family and cell death Blood, 88: 386-401, 1996.
47. Oltvai, Z., Milliman, C., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homologue, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.